MedTrace Logo

Validation of 3-[11C]-OHB

NCT05232812 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-03-31

No results posted yet for this study

Summary

Ketone bodies are produced in the liver at high levels of fatty acids, and act as an important source of energy for the brain and heart during fasting. The energy production from ketone metabolism is less oxygen-demanding than both glucose and fatty acid metabolism, and ketone substances can therefore be a very energy-efficient substrate for the heart. Insulin-resistant people as well as people with heart disease have difficulty burning glucose in the heart due to the insulin resistant condition and are therefore dependent on other energy sources such as free fatty acids and ketones. Because ketones are oxygen-sparing compared to fatty acids, interventions that increase the level of ketone bodies can potentially reduce the heart's need for oxygen in patients with narrowed coronary arteries. PET/CT is a functional and non-invasive imaging modality and suitable for tracking the fate of metabolites non-invasively, as most substrates or metabolites can be labeled by a PET isotope.

The purpose of this experiment is therefore to validate a new ketone tracer called 3-\[11C\]-OHB. Implementation of the 3-\[11C\]-OHB tracer will in future allow the investigators to more directly estimate the impact of different levels of ketone bodies on organ functions by measuring tissue-specific ketone uptake, both after intravenous and oral administration.

Conditions

Interventions

RADIATION

3-[11C]-OHB

The PET tracer 3-\[11C\]-OHB is used to quantify 3-hydroxybutyrate uptake

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-03-29
Completion
2023-03-29

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05232812 on ClinicalTrials.gov